Company intelligence / Profile preview

Retica

Cambridge, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Retica Pharmaceuticals was a biotechnology company focused on the development of small molecule therapeutics for the treatment of retinal diseases. The company's primary research efforts targeted conditions such as age-related macular degeneration (AMD) and diabetic retinopathy, which are leading causes of vision loss. Retica's approach involved the discovery of novel compounds designed to inhibit key pathways involved in ocular neovascularization and inflammation. Although the company advanced several candidates through early-stage research, it is no longer active in the clinical development space.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Retica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retica.

Explore the full profile